Therapeuticsmd Inc (NYSEMKT:TXMD) Institutional Investor Sentiment Is 1.85

TherapeuticsMD, Inc. (NASDAQ:TXMD) Logo

Sentiment for Therapeuticsmd Inc (NYSEMKT:TXMD)

Therapeuticsmd Inc (NYSEMKT:TXMD) institutional sentiment increased to 1.85 in 2019 Q1. Its up 0.99, from 0.86 in 2018Q4. The ratio has increased, as 76 funds started new or increased equity positions, while 41 sold and decreased their stock positions in Therapeuticsmd Inc. The funds in our partner’s database now hold: 184.60 million shares, up from 183.38 million shares in 2018Q4. Also, the number of funds holding Therapeuticsmd Inc in their top 10 equity positions increased from 0 to 2 for an increase of 2. Sold All: 13 Reduced: 28 Increased: 49 New Position: 27.

TherapeuticsMD, Inc. operates as a womenÂ’s health care product company. The company has market cap of $603.06 million. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

The stock decreased 1.96% or $0.05 during the last trading session, reaching $2.5. About 1.38M shares traded. TherapeuticsMD, Inc. (NYSEMKT:TXMD) has declined 45.29% since July 14, 2018 and is downtrending. It has underperformed by 49.72% the S&P500.

Analysts await TherapeuticsMD, Inc. (NASDAQ:TXMD) to report earnings on July, 29. They expect $-0.17 earnings per share, down 13.33 % or $0.02 from last year’s $-0.15 per share. After $-0.16 actual earnings per share reported by TherapeuticsMD, Inc. for the previous quarter, Wall Street now forecasts 6.25 % negative EPS growth.

Daruma Capital Management Llc holds 3.94% of its portfolio in TherapeuticsMD, Inc. for 7.11 million shares. 1492 Capital Management Llc owns 654,207 shares or 2.7% of their US portfolio. Moreover, J. Goldman & Co Lp has 0.54% invested in the company for 1.98 million shares. The California-based Nicholas Investment Partners Lp has invested 0.41% in the stock. Morgens Waterfall Vintiadis & Co Inc, a New York-based fund reported 112,000 shares.

Since January 1, 0001, it had 1 insider buy, and 0 selling transactions for $99,870 activity.

More notable recent TherapeuticsMD, Inc. (NASDAQ:TXMD) news were published by: which released: “Soft guidance pressures TherapeuticsMD, down 5% – Seeking Alpha” on June 10, 2019, also with their article: “Health Care Sector Update for 04/17/2019: ONCS, TXMD, ABT, JNJ, PFE, MRK, AMGN – Nasdaq” published on April 17, 2019, published: “Is TherapeuticsMD Inc (TXMD) A Good Stock To Buy? – Yahoo Finance” on May 03, 2019. More interesting news about TherapeuticsMD, Inc. (NASDAQ:TXMD) were released by: and their article: “Bullish Two Hundred Day Moving Average Cross – TXMD – Nasdaq” published on February 04, 2019 as well as‘s news article titled: “Health Care Sector Update for 04/17/2019: IONS,NVS,MASI,TXMD,ONCS – Nasdaq” with publication date: April 17, 2019.

TherapeuticsMD, Inc. (NASDAQ:TXMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.